This clinical trial is focused on studying a treatment for Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study is specifically for patients whose disease has returned or has not responded to previous treatments, including a medication called Lenalidomide. The main treatment being tested is a new type of therapy called BMS-986393, also known as GPRC5D-directed CAR T Cell Therapy. This therapy involves using a patient’s own T-cells, which are a type of immune cell, that have been modified to better recognize and attack cancer cells. The study will compare this new treatment to standard treatments, which include combinations of drugs like Daratumumab, Pomalidomide, and Dexamethasone, or Carfilzomib with Dexamethasone.
The purpose of the study is to determine if the new therapy works better than the standard treatments. Participants will receive either the new therapy or one of the standard treatments. The study will monitor how long participants live without their cancer getting worse and whether they achieve a state where no signs of cancer can be found in their body. The study will also look at overall survival, which is the average time participants are alive after starting the study, and how many participants show a positive response to the treatment.
Participants in the study will be adults who have received 1-3 previous treatments for Multiple Myeloma and have evidence that their disease worsened during or after their last treatment. The study will take place over several years, with an estimated end date in 2032. The goal is to find out if the new therapy can provide better outcomes for patients with this challenging condition.



Austria
Belgium
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
Italy
Norway
Poland
Portugal
Romania
Spain
Sweden
The Netherlands